Long-term Results After Transcatheter Aortic Valve Implantation: What do we Know Today?

Y. Elhmdi*, S. Bleiziffer, N. Piazza, B. Voss, M. Krane, M-A. Deutsch and R. Lange

Department of Cardiovascular Surgery, German Heart Centre Munich, Munich, Germany

Abstract: Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single-center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage after TAVI remains an important issue in this rapidly evolving field.

Keywords: Aortic valve, TAVI, paravalvular leakage, aortic stenosis, SAVR.

INTRODUCTION

Aortic stenosis (AS) is the most common valvular disease in the world. The surgical therapy is currently the gold standard for the treatment of the calcified stenotic valve [1]. With medical therapy only, the prognosis is very poor with a 3-year survival rate of <30% [1]. However, more than 30% of all patients aged > 70 years presented with severe aortic stenosis are deemed to be at high risk for surgical aortic valve replacement (SAVR) [2]. Patients undergoing only medical therapy or balloon valvuloplasty, have a poor prognosis with heart failure and higher mortality [3].

Transcatheter aortic valve implantation is a novel and rapidly evolving technique. It was first introduced in 2002 and is currently available as an alternative to conventional AVR for patients with severe symptomatic AS who are deemed to be at high risk for open heart surgery. Several studies showed the feasibility and safety of TAVI in those patients with high STS and EuroSCORES (scores for predicted operative mortality) [4, 5]. Patients following TAVI demonstrated hemodynamics and symptoms relief [6, 7]. Moreover, an immediate left ventricular improvement has been shown as well [8-11]. Early outcome and survival data have been previously reported in small controlled feasibility trials and single-center experience reports [6, 12]. Currently, first reports about the outcomes after TAVI including patients beyond a two-year follow-up period are available.

This review summarizes the most recent data published concerning the long-term results of patients undergoing TAVI including mortality, durability and hemodynamic performance up to 3 years.

EARLY MORTALITY AND LONG-TERM SURVIVAL

The most recent TAVI studies showed improved 30-day and 1-year survival with growing experience. The first transfemoral and transapical TAVI experiences demonstrated a higher 30-day mortality ranging from 12 to 15% and in some series up to 20% [13, 14]. Most centres demonstrated a learning curve with better results and less intra- and postprocedural complications over time [15, 16]. Devices techniques, MSCT imaging, risk calculations, patient’s selection and the introduction of a multidisciplinary team are factors which lead to an increasing implantation success [17].

The published data for long-term survival are shown in Table 1. There are very few data demonstrating the long-term survival in patients following TAVI. Most centres began with a TAVI program in 2009. Walther et al. presented recently the results of TAVI at 3-year follow up. A total of 299 patients underwent transapical aortic valve implantation from February 2006 until January 2010 using the Edwards SAPIEN transcatheter prosthesis. In their study, the 30-day survival was 91%, 73% at 1 year, 68% at 2 years, and 58% at 3 years [18]. Gurvitch et al. presented the long-term results of transfemoral and transapical Edwards Sapien implantation in one single-center in 70 patients during a mean follow up of 3.7 years. Similar to the previous study, the 1-year, 2-year and 3-year survival rates were 81%, 74% and 61%, respectively [19]. Congruent to these results, Ussia et al. presented the long-term outcomes of a large Italian registry undergoing TAVI with the Medtronic CoreValve device. The survival rate at 1-year, 2-year and 3-year were 76.4%, 69.7% and 56.2% respectively [20].

Bleiziffer et al. presented recently the 2-year results in 227 patients following transfemoral and transapical TAVI. The Medtronic CoreValve prosthesis was implanted in 174 patients and the Sapien Edwards prosthesis in 53 patients. The early and long-term mortality rates were not different from previous reports. The survival rates at 30-day, 1-year
and 2-year were 88.5%, 74.5% and 64.4% respectively [21]. According to their findings the majority of deaths occurred within the first 6 months after TAVI.

A recent multicenter single-arm study with symptomatic patients with severe aortic stenosis undergoing TAVI demonstrates a 30-day all-cause mortality of 15.2% and a 2-year survival of 61.9% [22]. The study evaluated the durability of both safety and efficacy of TAVI using the Medtronic Core-Valve prosthesis. In summary, death after TAVI occurred with an incidence density of 10.0% at 1 year and 1/3 of deaths were observed within the first 30 days after the procedure [23].

**DEVICE PERFORMANCE AND DURABILITY**

The device performance and durability is still subject of investigation. The published TAVI studies presented excellent postoperative device function, however, long-term results of device durability are still lacking. Concerns about tissue deterioration, endocarditis and tissue injury through crimping and after balloon dilatation, frame fracture and valve migration have been largely discussed and may potentially impact long-term valve function.

The excellent device performance for transcatheter aortic valves is inasmuch tempered by the increased risk of paravalvular leakage, caused by the native valve cusp calcifications which remain in situ. The incidence of moderate paravalvular regurgitation is ranging from 4% to 40% [24, 25]. In high risk patients with severe comorbidities, a moderate or high grade paravalvular leak is an additional risk for prolonged intubation, hospital stay, renal insufficiency and in some cases a subsequent SAVR was necessary. Indeed, most paravalvular leaks are mild to moderate depending on the implanted valves [12, 23, 26]. More importantly, patients who undergo SAVR after TAVI for severe paravalvular leak are at high risk for in-hospital morbidity and mortality [12]. The rates of moderate paravalvular leakage are shown in Table 2 and range from 4% to 15%. Usually, the initial AR after TAVI stays unchanged and no progression to severe AR is described over time [27, 28]. The recently published study from Unbehaun et al. [29] described the incidence and prognostic value of paravalvular leakage after TAVI. According to their findings, the cumulative survival rate was not dependent on post-procedural AR. The PARTNER Trial however raised concern that even mild aortic regurgitation was associated with late mortality after TAVI. Results after 2 years showed that mild aortic regurgitation was associated with increased long-term mortality [29].

All previous studies documented no evidence of structural valve deterioration or significant changes of the hemodynamic status of the prostheses [20-22] (Table 3). Leaflet deterioration after TAVI has been published in only one single case report. Ong et al. demonstrated a remarkable degeneration of a CoreValve pros thesis five years after implantation [30]. Such cases are rare; however, this may become an issue if TAVI is applied in younger patients.

In all studies, the incidence of endocarditis was very low. Walther et al. reported only one case of endocarditis (0.4%) [18]. The SOURCE registry [6] reported an incidence of only 1%. Gurvitch et al. observed in only 1.4% of all patients a valve endocarditis. However, late follow-up data in these patients remain relatively sparse [19].

The hemodynamics and valve efficacy were assessed by echocardiographic controls up to 3 years follow up (Fig. 1).

### Table 1. Patients characteristics and survival at 30 day, 1-2 and 3-year.

| Study           | Age (years) | Patients | LES (%) | STS (%) | 30-day (%) | 1-year (%) | 2-year (%) | 3-year (%) |
|-----------------|-------------|----------|---------|---------|------------|------------|------------|------------|
| Walther et al.  | 82 ± 6      | 299      | 31 ± 16 | 12 ± 8  | 91         | 73         | 68         | 58         |
| Gurvitch et al. | 84 ± 7      | 70       | 31.7 ± 16| 9.6 ± 3.5| n.a        | 81         | 74         | 61         |
| Ussia et al.    | 80.9 ± 6.1  | 181      | 24 ± 13.5| 11.4 ± 9.9| n.a        | 76.4       | 69.7       | 56.2       |
| Bleiziffer et al.| 81 ± 7      | 227      | 21 ± 14 | 7 ± 5   | 88.5       | 74.5       | 64.4       | n.a        |
| Buellesfeld et al. | 81.9 ± 6    | 126      | 23.4 ± 13| n.a    | 84.6       | n.a        | 61.9       | n.a        |

LES indicates logistic EuroSCORE, STS indicates Society of Thoracic Surgeons. n.a: not available.

### Table 2. The incidence of paravalvular leakage and progression over time.

|                        | Aortic Regurgitation (Moderate or Higher (%)) |
|------------------------|---------------------------------------------|
|                        | 30-day | 1-year | 2-year | 3-year |
| Walther et al. [18]    | 4      | 4      | 5      | 5      |
| Gurvitch et al. [19]   | 6      | 4      | n.a    | n.a    |
| Ussia et al. [20]      | 15.2   | 17.8   | n.a    | 10     |
| Bleiziffer et al. [21] | 13     | 15     | 14     | n.a    |
| Buellesfeld et al. [22]| 9      | 3      | 0      | n.a    |
All studies presented the effective orifice area (EOA) and transvalvular aortic mean gradients. In the study of Gurvitch et al., echocardiographic follow-up data were available in 37 patients. The mean aortic gradient decreased significantly from 45 mmHg to 10 mmHg after TAVI (p<0.01) with a subsequent increase to 12 mmHg after 3 years. The calculated aortic valve area increased significantly from $0.6 \pm 0.2$ cm$^2$ at baseline to $1.7 \pm 0.4$ cm$^2$ after TAVI with a subsequent attrition at 12 months to $1.5 \pm 0.3$ cm$^2$ and to $1.4 \pm 0.3$ cm$^2$ after 3 years [29]. In 89 patients who survived the 3 years follow up, Ussia et al. showed a significant decrease in the aortic mean gradient from 52 mmHg to 10.3 mmHg after 1 year and a gradient of 10.3 mmHg after 3 years follow up [20]. The calculated aortic valve area increased significantly from $0.6 \text{ cm}^2$ at baseline to $1.7 \text{ cm}^2$ after TAVI and remained unchanged after 3 years (1.7 cm$^2$). The study of Bleiziffer et al. confirmed all previous findings. The mean aortic gradient decreased significantly from 48 mmHg at baseline to 12 mmHg at discharge with no changes over 2 years follow up. The calculated aortic valve area increased from $0.67 \text{ cm}^2$ at baseline to $1.55 \text{ cm}^2$ at discharge and remained unchanged 2 years after TAVI [21].

**Table 3. Major adverse outcome at 2/3 years.**

|                     | Walther et al. [18] | Gurvitch et al. [19] | Ussia et al. [20] | Bleiziffer et al. [21] | Builesfeld et al. [22] |
|---------------------|---------------------|----------------------|-------------------|------------------------|------------------------|
| Stroke (%)          | n.a                 | 8.6                  | 3.9               | 6.6                    | 13.5                   |
| Myocardial infarction (%) | n.a                 | 8.6                  | 1.1               | 2.7                    | 6.3                    |
| Reoperation (%)     | n.a                 | 1.4                  | 0                 | n.a                    | 9.3                    |
| Bleeding (major) (%)| n.a                 | 7.1                  | 10.5              | 4.8                    | n.a                    |
| Endokarditis (%)    | n.a                 | 1.4                  | n.a               | n.a                    | 0.8                    |
| Structural valve deterioration (%) | n.a                 | 0                    | 0                 | n.a                    | 0                      |
| Valve thrombosis (%) | n.a                 | 0                    | n.a               | n.a                    | 0                      |

Fig. (1). The hemodynamical changes in (A) Aortic mean gradient and (B) Effective orifice area (EOA) in all studies.

All studies presented the effective orifice area (EOA) and transvalvular aortic mean gradients. In the study of Gurvitch et al., echocardiographic follow-up data were available in 37 patients. The mean aortic gradient decreased significantly from 45 mmHg to 10 mmHg after TAVI (p<0.01) with a subsequent increase to 12 mmHg after 3 years. The calculated aortic valve area increased significant from $0.6 \pm 0.2$ cm$^2$ at baseline to $1.7 \pm 0.4$ cm$^2$ after TAVI with a subsequent attrition at 12 months to $1.5 \pm 0.3$ cm$^2$ and to $1.4 \pm 0.3$ cm$^2$ after 3 years [29]. In 89 patients who survived the 3 years follow up, Ussia et al. showed a significant decrease in the aortic mean gradient from 52 mmHg to 10.3 mmHg after 1 year and a gradient of 10.3 mmHg after 3 years follow up [20]. The calculated aortic valve area increased significantly from $0.6 \text{ cm}^2$ at baseline to $1.7 \text{ cm}^2$ after TAVI and remained unchanged after 3 years (1.7 cm$^2$). The study of Bleiziffer et al. confirmed all previous findings. The mean aortic gradient decreased significantly from 48 mmHg at baseline to 12 mmHg at discharge with no changes over 2 years follow up. The calculated aortic valve area increased from $0.67 \text{ cm}^2$ at baseline to $1.55 \text{ cm}^2$ at discharge and remained unchanged 2 years after TAVI [21].

**NEUROLOGICAL EVENTS IN FOLLOW UP**

The major neurological adverse outcomes are illustrated in Table 3. In the PARTNER Trial, the neurologic events were 2-fold higher in TAVI patients than in SAVR (5.5 vs 2.4% at 30-days, p=0.04, respectively). Moreover, 50% of all strokes occurred during the first 24h after the implantation with a peaking high hazard phase in the first postoperative week [31, 32]. The recently published study from Miller et al. described possible risk factors for early and late neurological events occurring in the PARTNER Trial. The risk of late stroke is influenced by patient’s comorbidities [31]. Those factors included advanced functional impairment (NYHA class) and history of stroke within 6 to 12 months before TAVI.

Among all studies, the stroke rate at 2-3 years was different and ranged from 3.9% to 13.5%. Different definitions of neurological events could explain the divergence in the percentage reported in all studies. Such differences in endpoint definitions should be eliminated in the future by using the standardized VARC criteria [33].

**CONCLUSIONS**

TAVI exhibits excellent hemodynamic and clinical improvement in patients presented with high surgical risk for SAVR. The improvement sustained up to 3 years follow up with a survival rate of approximately 60%. Valve deterioration and tissue endocarditis are very rare even at 3 years follow up. However, the aortic insufficiency after TAVI remains an important issue in this rapidly evolving field.
CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Schwarz F, P Baumann, J Manthey, et al. The effect of aortic valve replacement on survival. Circulation 1982; 66(5): 1105-10.

[2] Yan TD, C Cao, J Martens-Nielsen, et al. Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review. J Thorac Cardiovasc Surg 2010; 139(6): 1528-36.

[3] Leon MB, CR Smith, M Mack, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363(17): 1597-607.

[4] Grube, E., G. Schuler, L. Buellesfeld, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 2007; 50(1): 69-76.

[5] Webb JG, S Pasupati, K Humphries, et al. Percutaneous transaortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007; 116(7): 755-63.

[6] Thomas M, G Schymik, T Walther, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2011; 124(4): 425-33.

[7] Bleiziffer S, H Rugge, D Mazzitelli, et al. Valve implantation on the beating heart: catheter-assisted surgery for aortic stenosis. Dtsch Arztebl Int 2009; 106(14): 235-41.

[8] van der Boon RM, Nuis RJ, Van Mieghem NM, et al. Clinical outcome following transcatheter aortic valve implantation in patients with impaired left ventricular systolic function. Catheter Cardiovasc Interv 2012; 79(5): 702-10.

[9] Pilgrim T, P Wennaweser, F Meuli, et al. Clinical Outcome of High-Risk Patients with Severe Aortic Stenosis and Reduced Left Ventricular Ejection Fraction Undergoing Medical Treatment or TAVI. PLoS One 2011; 6(11): e27556.

[10] Gottzmann M, M Lindstaedt, W Bojara, W Ewers, A Mugge, et al. Aortic valve implantation in patients with low-flow, low gradient aortic stenosis. Catheter Cardiovasc Interv 2012; 79(5): 693-701.

[11] Ewe SH, N Ajmone Marsan, M Pepi, et al. Impact of left ventricular systolic function on clinical and echocardiographic outcomes following transcatheter aortic valve implantation for severe aortic stenosis. Am Heart J 2010; 160(6): 1113-20.

[12] Unbehauen A, M Pasie, S Dreyssse, et al. Transcatheter aortic valve implantation: incidence and predictors of paravalvular leakage and transvalvular regurgitation in a series of 358 patients. J Am Coll Cardiol 2012; 59(3): 211-21.

[13] Grube E, JC Laborde, U Gerckens, et al. Percutaneous implantation of the CoreValve Self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Sieburg first-in-man study. Circulation 2006; 114(15): 1616-24.

[14] Svensson LG, T Dewey, S Kapadia, et al. United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg 2008; 86(1): 46-54; discussion 54-5.

[15] Lange R, S Bleiziffer, N Piazza, et al. Incidence and treatment of procedural cardiovascular complications associated with transarterial and trans-apical interventional aortic valve implantation in 412 consecutive patients. Eur J Cardiothorac Surg 2011; 40(5): 1105-13.

[16] Kempfert J, A Rastan, D Holzhey, et al. Transapical aortic valve implantation: analysis of risk factors and learning experience in 299 patients. Circulation 2011; 124(11 Suppl): S124-9.

[17] Lange R, S Bleiziffer, D Mazzitelli, et al. Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future. J Am Coll Cardiol 2012; 59(3): 280-7.

[18] Walther T, J Kempfert, A Rastan, et al. Transapical aortic valve implantation at 3 years. J Thorac Cardiovasc Surg 2012; 143(2): 326-31.

[19] Gurvitch R, DA Wood, EL Tay, et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. Circulation 2010; 122(13): 1319-27.

[20] Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J 2012; 33(8): 969-76.

[21] Bleiziffer S, D Mazzitelli, A Opitz, et al. Beyond the short-term: clinical outcome and valve performance 2 years after transcatheter aortic valve implantation in 227 patients. J Thorac Cardiovasc Surg 2012; 143(2): 310-7.

[22] Buellesfeld L, U Gereckens, G Schuler, et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Coll Cardiol 2011; 57(16): 1650-7.

[23] Tamburino C, D Capodanno, A Ramondo, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011; 123(5): 299-308.

[24] Smith CR, MB Leon, MJ Mack, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.

[25] Gurvitch R, JG Webb, R Yuan, et al. Aortic annulus diameter determination by multidetector computed tomography: reproducibility, applicability, and implications for transcatheter aortic valve implantation. JACC Cardiovasc Interv 2011; 4(11): 1235-45.

[26] Rodes-Cabau J, JG Webb, A Cheung, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55(11): 1080-90.

[27] Gottzmann M, M Lindstaedt, W Bojara, A Mugge, and A Germing. Hemodynamic results and changes in myocardial function after transcatheter aortic valve implantation. Am Heart J 2010; 159(5): 926-32.

[28] Rajani R, M Kakad, MZ Khawaja, et al. Paravalvular regurgitation one year after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010; 75(6): 868-72.

[29] Kodali SK, Williams MR, Smith CR, et al. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med 2012; 366: 1686-95.

[30] Ong SH, R Mueller, and S Iversen. Early calcific degeneration of a CoreValve transcatheter aortic bioprosthesis. Eur Heart J 2012; 33(5): 586.

[31] Miller DC, EH Blackstone, MJ Mack, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 2012; 143(4): 832-843 e13.

[32] Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Frequency and Causes of Stroke During or After Transcatheter Aortic Valve Implantation. Am J Cardiol 2012; 109(11): 1637-43.

[33] Leon MB, N Piazza, E Nikolsky, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 2011; 57(3): 253-69.